OptiNose News - OPTN

Company Name	Stock Ticker Symbol	Market	Type
OptiNose Inc	OPTN	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	0.0223	2.40%	0.95	20:00:00

Open Price	Low Price	High Price	Close Price	Prev Close
0.9327	0.8942	0.965499	0.8942	0.9277

more quote information »

Recent News

Date	Time	Source	Heading
4/04/2024	16:01	GLOBE	Optinose to Present at the Needham Virtual Healthcare..
3/15/2024	15:34	GLOBE	XHANCE Approved by FDA as First and Only Medication..
3/08/2024	16:10	EDGAR2	Form 8-K - Current report
3/07/2024	16:32	EDGAR2	Form S-8 - Securities to be offered to employees in employee..
3/07/2024	07:01	EDGAR2	Form 10-K - Annual report [Section 13 and 15(d), not S-K..
3/07/2024	07:00	GLOBE	Optinose Reports Fourth Quarter and Full Year 2023 Financial..
3/07/2024	07:00	EDGAR2	Form 8-K - Current report
2/29/2024	16:40	GLOBE	Optinose Announces Reporting Date for Fourth Quarter 2023..
2/29/2024	16:07	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2/29/2024	16:06	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2/29/2024	16:05	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2/29/2024	16:04	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2/23/2024	07:08	EDGAR2	Form 8-K - Current report
2/22/2024	16:28	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
2/14/2024	20:48	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
2/13/2024	17:16	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
2/01/2024	14:43	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
1/30/2024	16:05	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
1/18/2024	12:00	GLOBE	Optinose Announces the Publication of ReOpen Phase 3..
12/21/2023	16:11	EDGAR2	Form 8-K - Current report
12/20/2023	12:21	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/20/2023	12:20	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/06/2023	08:48	DJN	Optinose Shares Slide Premarket as FDA Extends Xhance Review
12/06/2023	07:02	EDGAR2	Form 8-K - Current report
12/06/2023	07:00	GLOBE	Optinose Announces 3-Month Extension of FDA Review Period..
11/22/2023	09:00	GLOBE	Optinose to Present at the 35th Annual Piper Sandler..
11/09/2023	07:03	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/09/2023	07:02	EDGAR2	Form 8-K - Current report
11/09/2023	07:00	GLOBE	Optinose Reports Third Quarter 2023 Financial Results and..
10/27/2023	08:00	GLOBE	Optinose Announces Reporting Date for Third Quarter 2023..
9/22/2023	09:01	GLOBE	Optinose to Present at the 2023 Cantor Global Healthcare..
9/19/2023	19:05	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
9/19/2023	19:04	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/18/2023	00:15	EDGAR2	Form EFFECT - Notice of Effectiveness
8/10/2023	16:05	EDGAR2	Form S-3 - Registration statement under Securities Act of..
8/10/2023	07:11	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/10/2023	07:02	EDGAR2	Form 8-K - Current report
8/10/2023	07:00	GLOBE	Optinose Reports Second Quarter 2023 Financial Results and..
7/27/2023	07:27	EDGAR2	Form 8-K - Current report
7/27/2023	07:00	GLOBE	Optinose Announces Preliminary Second Quarter 2023 XHANCE..
6/16/2023	16:08	GLOBE	Optinose Announces Inducement Grant Under Nasdaq Listing..
6/02/2023	13:00	GLOBE	Optinose to Present at the Jefferies Healthcare Conference
5/11/2023	07:00	GLOBE	Optinose Reports First Quarter 2023 Financial Results and..
5/04/2023	07:00	GLOBE	Optinose Announces FDA Acceptance of Supplemental New Drug..
5/01/2023	16:30	GLOBE	Optinose Announces Reporting Date for First Quarter 2023..